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Database search strategy
'measles vaccine'/mj OR 'measles mumps rubella vaccine'/mj OR 'measles rubella vaccine'/mj OR 'measles mumps vaccine'/mj OR ('measles vaccine'/de AND ('vaccination'/mj OR 'immunization'/mj)) 3.
('measles'/mj OR 'measles virus'/mj) AND ('vaccination'/mj OR 'immunization'/mj) 4.
#1 OR #2 OR #3 5.
'before 9 months':ti,ab OR ('less than' NEAR/4 '9 months'):ti,ab OR (earlier NEAR/4 '9 months'):ti,ab OR 'under 9 months':ti,ab OR 'below 9 months':ti,ab OR ('younger than' NEAR/4 '9 months'):ti,ab 6.
'0 month*':ti,ab OR '1 month*':ti,ab OR '2 month*':ti,ab OR '3 month*':ti,ab OR '4 month*':ti,ab OR '5 month*':ti,ab OR '6 month*':ti,ab OR '7 month*':ti,ab OR '8 month*':ti,ab OR '9 month*':ti,ab OR '1-2 month*':ti,ab OR '1-3 month*':ti,ab OR '1-4 month*':ti,ab OR '1-5 month*':ti,ab OR '1-6 month*':ti,ab OR '1-7 month*':ti,ab OR '1-8 month*':ti,ab OR '1-9 month*':ti,ab OR '2-3 month*':ti,ab OR '2-4 month*':ti,ab OR '2-5 month*':ti,ab OR '2-6 month*':ti,ab OR '2-7 month*':ti,ab OR '2-8 month*':ti,ab OR '2-9 month*':ti,ab 7.
'3-4 month*':ti,ab OR '3-5 month*':ti,ab OR '3-6 month*':ti,ab OR '3-7 month*':ti,ab OR '3-8 month*':ti,ab OR '3-9 month*':ti,ab OR '4-5 month*':ti,ab OR '4-6 month*':ti,ab OR '4-7 month*':ti,ab OR '4-8 month*':ti,ab OR '4-9 month*':ti,ab OR '5-6 month*':ti,ab OR '5-7 month*':ti,ab OR '5-8 month*':ti,ab OR '5-9 month*':ti,ab OR '6-7 month*':ti,ab OR '6-8 month*':ti,ab OR '6-9 month*':ti,ab OR '7-8 month*':ti,ab OR '7-9 month*':ti,ab OR '8-9 month*':ti,ab 8.
' 'first month*':ti,ab OR 'second month*':ti,ab OR 'third month*':ti,ab OR 'fourth month*':ti,ab OR 'fifth month*':ti,ab OR 'first two month*':ti,ab OR 'first three month*':ti,ab OR 'first four month*':ti,ab OR 'first five month*':ti,ab OR 'first six month*':ti,ab OR 'first seven month*':ti,ab OR 'first eight month*':ti,ab OR 'first nine month*':ti,ab OR 'first 2 month*':ti,ab OR 'first 3 month*':ti,ab OR 'first 4 month*':ti,ab OR 'first 5 month*':ti,ab OR 'first 6 month*':ti,ab OR 'first 7 month*':ti,ab OR 'first 8 month*':ti,ab OR 'first 9 month*':ti,ab 10.
(weeks NEAR/4 age):ti,ab 11.
'4.5 months':ti,ab OR ('first dose':ti,ab AND (before NEAR/9 months):ti,ab) 12.
(early NEAR/3 vaccination):ti,ab OR (early NEAR/3 immunization):ti,ab OR (early NEAR/3 immunisation):ti,ab OR (early NEAR/3 mv):ti,ab OR (early NEAR/3 schedule):ti,ab OR 'give earlier':ti,ab OR 'early mv':ti,ab OR 'primary mv':ti,ab OR 'given earlier':ti,ab OR 'early infancy':ti,ab 13.
#4 AND (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12) 14.
immunogenicity:ti,ab,de OR efficacy:ti,ab,de OR effectiveness:ti,ab,de OR effectivity:ti,ab,de OR 'immunological impact':ti,ab,de OR 'immunogenicity'/de OR 'vaccine immunogenicity'/de OR 'drug efficacy'/de OR 'optimal age':ti OR 'optimum age':ti 15.
'measles cases':ti,ab OR ('measles'/de AND 'incidence'/de) OR ('infant mortality'/de OR 'mortality'/de OR 'death'/de AND 'measles vaccine'/de) OR (measles NEAR/4 (death* OR mortality OR incidence)):ti,ab 16.
'virus antibody'/de OR 'neutralizing antibody'/de OR 'immunoglobulin g'/de OR 'enzymelinked immunosorbent assay'/de OR 'enzyme-linked immunospot assay'/de OR 'hemagglutination inhibition test'/de OR 'virus neutralization'/de OR 'serodiagnosis'/de 17.
'plaque reduction neutralization test*':ti,ab OR prnt:ti,ab OR 'enzyme-linked immunosorbent assay':ti,ab OR 'enzyme-linked immunospot assay':ti,ab OR elisa:ti,ab OR 'hemagglutination inhibition assay':ti,ab OR 'hi assay':ti,ab OR 'complement fixation assay':ti,ab OR 'cf assay':ti,ab OR avidity:ti,ab 18.
('measles vaccine'/de AND 'drug administration'/lnk) OR 'antibody production' OR 'antibody affinity'/de OR 'cellular immunity'/de OR 'lymphocyte activation'/de OR 'cytopathogenic effect'/de OR ('stimulation index':ti,ab AND 't-cell proliferation':ti,ab) 19.
'antibody response*':ti,ab OR 'antibody titer*':ti,ab OR 'antibody titre*':ti,ab OR 'antibody level*':ti,ab OR 'immune response*':ti,ab OR 't-cell response*':ti,ab OR 'cell-mediated immunity':ti,ab OR (humoral NEAR/3 immunity):ti,ab OR 'measles igg':ti,ab OR seroconversion:ti,ab OR 'response to vaccination':ti,ab OR (response NEAR/3 'measles vaccination'):ti,ab 20.
(improve NEAR/3 survival):ti,ab OR (improves NEAR/3 survival):ti,ab OR 'mortality reduction':ti,ab OR 'child mortality':ti,ab OR (prevention NEAR/3 measles):ti,ab OR (risk NEAR/3 measles):ti,ab 21.
reactogenicity:ti,ab,de OR safety:ti,ab,de OR 'adverse events':ti,ab,de OR 'adverse effects':ti,ab,de OR 'side effects':ti,ab,de OR fever:ti,ab,de OR 'local reaction*':ti,ab,de OR convulsion*:ti,ab,de OR purpura:ti,ab,de OR rash:ti,ab,de 22.
'aseptic meningitis':ti,ab OR seizures:ti,ab OR encephalopathy:ti,ab OR anaphylaxis:ti,ab OR hypersensitivity:ti,ab OR 'allergic reaction*':ti,ab OR 'joint pain':ti,ab OR arthropathy:ti,ab OR arthralgia:ti,ab OR arthritis:ti,ab OR cough:ti,ab OR diarrhoea:ti,ab OR diarrhea:ti,ab 23.
'measles vaccine'/de OR 'measles mumps rubella vaccine'/de OR 'measles rubella vaccine'/de OR 'measles mumps vaccine'/de AND ('adverse drug reaction'/lnk OR 'side effect'/lnk) 24.
'measles vaccine'/de OR 'measles mumps rubella vaccine'/de OR 'measles rubella vaccine'/de OR 'measles mumps vaccine'/de AND ('adverse events':de OR 'side effects':de OR 'chemically induced':de OR complications:de OR contraindications:de OR toxicity:de OR poisoning:de OR 'drug effects':de) 25.
(adverse:ti,ab AND (effect*:ti,ab OR event*:ti,ab)) OR 'side effect*':ti,ab OR hypersensitiv*:ti,ab OR sensitiv*:ti,ab OR safe*:ti,ab OR pharmacovigil*:ti,ab 26.
#13 AND (#14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25) 27.
english:la OR dutch:la OR german:la OR french:la OR spanish:la 28.
#26 AND #27 29.
[ #1 OR #2 4.
TITLE-ABS-KEY((before-9-months) OR ((less-than) W/4 (9-months)) OR (earlier W/4 (9-months)) OR (under-9-months) OR (below-9-months) OR ((younger-than) W/4 (9-months))) 5.
TITLE-ABS-KEY((0-month*) OR (1-month*) OR (2-month*) OR (3-month*) OR (4-month*) OR (5-month*) OR (6-month*) OR (7-month*) OR (8-month*) OR (9-month*) OR (1-2-month*) OR (1-3-month*) OR (1-4-month*) OR (1-5-month*) OR (1-6-month*) OR (1-7-month*) OR (1-8-month*) OR (1-9-month*) OR (2-3-month*) OR (2-4-month*) OR (2-5-month*) OR (2-6-month*) OR (2-7-month*) OR (2-8-month*) OR (2-9-month*)) 6.
TITLE-ABS-KEY ((3-4-month*) OR (3-5-month*) OR (3-6 month*) OR (3-7 month*) OR (3-8 month*) OR (3-9 month*) OR (4-5-month*) OR (4-6-month*) OR (4-7-month*) OR (4-8-month*) OR (4-9-month*) OR (5-6-month*) OR (5-7-month*) OR (5-8-month*) OR (5-9-month*) OR (6-7-month*) OR (6-8-month*) OR (6-9-month*) OR (7-8-month*) OR (7-9-month*) OR (8-9-month*)) 7.
TITLE TITLE-ABS-KEY((first-month*) OR (second-month*) OR (third-month*) OR (fourthmonth*) OR (fifth-month*) OR (sixth-month*) OR (seventh-month*) OR (eigth-month*) OR (firsttwo-month*) OR (first-three month*) OR (first-four-month*) OR (first-five month*) OR (first-six month*) OR (first-seven month*) OR (first-eight month*) OR (first-nine month*) OR (first-2-month*) OR (first-3-month*) OR (first-4-month*) OR (first-5-month*) OR (first-6-month*) OR (first-7-month*) OR (first-8-month*) OR (first-9-month*)) 9.
TITLE-ABS-KEY(weeks W/4 age) 10.
TITLE-ABS-KEY(4.5-months) OR (TITLE-ABS-KEY(first-dose) AND TITLE-ABS-KEY(before W/9 months)) 11. TITLE-ABS-KEY((early W/3 vaccination) OR (early W/3 immunization) OR (early W/3 immunisation) OR (early W/3 mv) OR (early W/3 schedule) OR (give-earlier) OR (early-mv) OR (primary-mv) OR (given-earlier) OR (early-infancy)) 12.
#3 AND (#4 OR #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11) 13.
TITLE-ABS-KEY(immunogenic* OR efficacy OR effectiveness OR effectivity OR (immunological-impact) OR immunogenicity) OR TITLE((optimal-age) OR (optimum-age)) 14.
TITLE-ABS-KEY((measles-cases) OR (measles AND incidence) OR ((mortality OR death) AND (measles-vaccin*))) OR TITLE-ABS-KEY(measles W/4 (death* OR mortality OR incidence)) 15.
TITLE-ABS-KEY((plaque-reduction-neutralization-test*) OR prnt OR (enzyme-linkedimmunosorbent-assay) OR (enzyme-linked-immunospot-assay) OR elisa OR (hemagglutinationinhibition assay) OR (hi-assay) OR (complement-fixation-assay) OR (cf-assay) OR avidity OR (virusanitibod*) OR (neutralizing-antibod*) OR (immunogloublin-g) OR (virus-neutralization) OR serodiagnosis) 16.
(KEY(measles vaccine) AND KEY(drug-administration)) OR KEY((antibody-production) OR (antibody-affinity) OR (cellular-immunity) OR (lymphocyte-activation) OR (cytopathogenic-effect) OR ((stimulation-index) AND (t-cell-proliferation))) 17.
TITLE-ABS-KEY((antibody-response*) OR (antibody-titer*) OR (antibody-titre*) OR (antibody-level*) OR (immune-response*) OR (t-cell-response*) OR (cell-mediated-immunity) OR (humoral W/3 immunity) OR (measles-igg) OR seroconversion OR (response-to-vaccination) OR (response W/3 (measles-vaccination))) 18.
TITLE-ABS-KEY((improve W/3 survival) OR (improves W/3 survival) OR (mortalityreduction) OR (child-mortality) OR (prevention W/3 measles) OR (risk W/3 measles)) 19.
TITLE-ABS-KEY(reactogenicity OR safety OR (adverse-events) OR (adverse-effects) OR (side-effects) OR fever OR (local-reaction*) OR convulsion* OR purpura OR rash) 20.
TITLE-ABS-KEY((aseptic-meningitis) OR seizures OR encephalopath* OR anaphylaxis OR hypersensitivity OR (allergic-reaction*) OR (joint-pain) OR arthropathy OR arthralgia OR arthritis OR cough OR diarrhoea OR diarrhea) 21.
KEY((measles-vaccine) OR (measles-mumps-rubella-vaccine) OR (measles-rubella vaccine) OR (measles-mumps-vaccine) ) AND KEY((adverse-drug-reaction*) OR (adverse-effect*) OR (adverse-event*) OR (side-effect*) OR (chemically-induced) OR complications OR contraindications OR toxicity OR poisoning OR (drug-effects)) 22.
TITLE SU((measles-vaccine) OR (measles-mumps-rubella-vaccine) OR (measles-rubella vaccine) OR (measles-mumps-vaccine)) AND SU((adverse-drug-reaction*) OR (adverse-effect*) OR (adverseevent*) OR (side-effect*) OR (chemically-induced) OR complications OR contraindications OR toxicity OR poisoning OR (drug-effects)) 22.
TI,AB,SU(adverse W/5 (effect* OR event*)) OR TI,AB,SU((side-effect*) OR hypersensitiv* OR sensitiv* OR safe* OR pharmacovigil*) 23. S12 AND (S13 OR S14 OR S15 OR S16 OR S17 OR S18 OR S19 OR S20 OR S21 OR S22) 24.
LA 
Exclusion criteria
 Ecological studies, case reports, non-human primate studies, meeting abstracts, editorials, newspaper articles and other forms of popular media were excluded.
 High titre vaccines were excluded from the review, defined as vaccines with a TCID 50 of ≥4.7 or p.f.u. of ≥50,000 (F. Cutts, personal communication). Titres below this cut-off were assumed to be 'standard'. Study results derived from combining MCV with gamma globulin or obtained after intradermal (rather than subcutaneous) administration of MCV were also excluded from the review.
 Failure to meet any one of the above eligibility criteria.
Characteristics of studies included in the review by outcome 
GRADE summary of evidence table

